$1.30
6.56% day before yesterday
Nasdaq, May 02, 10:15 pm CET
ISIN
US0144421072
Symbol
ALEC
Sector
Industry

Alector, Inc. Stock price

$1.30
+0.12 10.17% 1M
-3.97 75.33% 6M
-0.59 31.22% YTD
-4.04 75.66% 1Y
-8.78 87.10% 3Y
-24.36 94.93% 5Y
-15.33 92.18% 10Y
Nasdaq, Closing price Fri, May 02 2025
+0.08 6.56%
ISIN
US0144421072
Symbol
ALEC
Sector
Industry

Key metrics

Market capitalization $129.99m
Enterprise Value $-240.89m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.04
EV/Sales (TTM) EV/Sales -2.40
P/S ratio (TTM) P/S ratio 1.29
P/B ratio (TTM) P/B ratio 1.02
Revenue growth (TTM) Revenue growth 3.60%
Revenue (TTM) Revenue $100.56m
EBIT (operating result TTM) EBIT $-142.79m
Free Cash Flow (TTM) Free Cash Flow $-231.16m
Cash position $413.40m
EPS (TTM) EPS $-1.24
P/E forward negative
P/S forward 12.15
EV/Sales forward negative
Short interest 7.97%
Show more

Is Alector, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,786 stocks worldwide.

Alector, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Alector, Inc. forecast:

5x Buy
71%
2x Sell
29%

Analyst Opinions

7 Analysts have issued a Alector, Inc. forecast:

Buy
71%
Sell
29%

Financial data from Alector, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
101 101
4% 4%
100%
- Direct Costs 8.84 8.84
0% 0%
9%
92 92
4% 4%
91%
- Selling and Administrative Expenses 49 49
8% 8%
48%
- Research and Development Expense 177 177
5% 5%
176%
-134 -134
6% 6%
-133%
- Depreciation and Amortization 8.84 8.84
0% 0%
9%
EBIT (Operating Income) EBIT -143 -143
6% 6%
-142%
Net Profit -119 -119
9% 9%
-118%

In millions USD.

Don't miss a Thing! We will send you all news about Alector, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alector, Inc. Stock News

Neutral
GlobeNewsWire
17 days ago
--76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerati...
Neutral
GlobeNewsWire
about one month ago
--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role--
Neutral
Seeking Alpha
2 months ago
Alector, Inc. (NASDAQ:ALEC ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Katie Hogan - Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal - Co-Founder and Chief Executive Officer Gary Romano - Chief Medical Officer Sara Kenkare-Mitra - President and Head, Research and Development Marc Grasso - Chief Financial Officer Conference...
More Alector, Inc. News

Company Profile

Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Head office United States
CEO Arnon Rosenthal
Employees 238
Founded 2013
Website www.alector.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today